You have accessJournal of UrologyInfertility: Therapy II1 Apr 2018MP07-18 THE USAGE RATE OF SEMEN CRYOPRESERVATION BEFORE CANCER TREATMENT Koji Chiba, Mikito Tanaka, Takaki Ishida, Kenta Sumii, Teruo Fukuda, Keisuke Okada, Kei Matsushita, and Masato Fujisawa Koji ChibaKoji Chiba More articles by this author , Mikito TanakaMikito Tanaka More articles by this author , Takaki IshidaTakaki Ishida More articles by this author , Kenta SumiiKenta Sumii More articles by this author , Teruo FukudaTeruo Fukuda More articles by this author , Keisuke OkadaKeisuke Okada More articles by this author , Kei MatsushitaKei Matsushita More articles by this author , and Masato FujisawaMasato Fujisawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.3081AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Due to recent advances in medical technologies, cancer has become more curable and chronic, and post-treatment quality of life, including male fertility, has become an important issue. Semen cryopreservation is generally recommended for patients who will receive cancer chemotherapy. We have retrospectively reviewed the usage rate of cryopreserved semen samples for cancer patients in our institution. METHODS This study included 57 patients who cryopreserved their semen before cancer treatment after 2008. Primary disease, age at semen cryopreservation, marriage status, semen parameters at cryopreservation and usage rate of cryopreserved semen were evaluated. RESULTS The proportion of primary diseases were as follows: testicular cancer 34 cases, hematological cancer 13 cases, bowel cancer 3 cases, bone or soft tissue malignancy 3 cases, brain cancer 3 cases and extra-gonadal germ cell tumor 1 case. Among all patients, 6 patients died of primary disease during the evaluated period. Median age at sperm cryopreservation was 29 years old. Semen volume, sperm concentration, sperm motility at cryopreservation were 2.8ml, 36 million /mL, 51%, respectively. Patients with testicular cancer showed more severely damaged semen parameters compared to patients with other malignancies. Six patients showed azoospermia at cryopreservation, and testicular sperm was obtained in 5 patients. Among all cohort, 6 patients (10.5%) used cryopreserved semen for intracytoplasmic sperm injection (ICSI), and live birth were confirmed in 4 couples. Cryopreserved semen were destroyed in 19 patients (patients’ death 5 cases, restoration of spermatogenesis 2 cases, unknown 12 cases). CONCLUSIONS In this study, the usage rate of cryopreserved semen was 10.5%. Although the usage rate of cryopreserved semen was not high, 4 live birth were achieved with ICSI. Because it is difficult to predict spermatogenic dysfunction after treatment, semen cryopreservation should be recommended before initiation of gonad-toxic chemotherapy. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e94-e95 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Koji Chiba More articles by this author Mikito Tanaka More articles by this author Takaki Ishida More articles by this author Kenta Sumii More articles by this author Teruo Fukuda More articles by this author Keisuke Okada More articles by this author Kei Matsushita More articles by this author Masato Fujisawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...